| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/27/2005 | US20050020500 Glycosaminoglycan-polypeptide complex; antiarthritic agents |
| 01/27/2005 | US20050020498 Apo-2 ligand/trail formulations |
| 01/27/2005 | US20050020492 Melanin-concentrating hormone analogs |
| 01/27/2005 | US20050020486 Product and composition containing a Concholepas concholepas hemocyanin (CCH) subunit, and a method of use thereof |
| 01/27/2005 | US20050020482 Methods for modulating gap junctions |
| 01/27/2005 | US20050019923 Nucleotide sequences comprising cationic polypropylenimine dendrimer and diaminobutane core for use as tool in delivery of drug agents and tissue targeted therapy |
| 01/27/2005 | US20050019889 Human osteoclast derived cathepsin |
| 01/27/2005 | US20050019872 PC-LECTIN protein; vaccines and diagnostic marker for prostate cancer |
| 01/27/2005 | US20050019835 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/27/2005 | US20050019832 IGF-1 receptor interacting proteins |
| 01/27/2005 | US20050019826 Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof |
| 01/27/2005 | US20050019821 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/27/2005 | US20050019812 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019811 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019783 Method of determining a chemotherapeutic regimen based on glutathione-s transferase pi expression |
| 01/27/2005 | US20050019768 Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas |
| 01/27/2005 | US20050019763 Isolated polypeptide of given sequence; expression vectors, host cells, antibodies, agonists, and antagonists; use in diagnosing, treating, or preventing various disorders |
| 01/27/2005 | US20050019437 Administering a photoestrogen for treating urinary bladder infection and dry vagina; plant extracts is obtained from solvent extraction |
| 01/27/2005 | US20050019424 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| 01/27/2005 | US20050019417 stabilization of proteins, peptides or cells by fluidization of microparticles to form fluidized bed of microparticles comprising water soluble gel forming solid particles, then spraying coating with liquids comprising sugars and solvents, and drying |
| 01/27/2005 | US20050019391 Orodispersible tablet having high homogeneity and the preparation method thereof |
| 01/27/2005 | US20050019386 In mixture of membrane-forming amphiphiles subjected to high pressure homogenization or ultrasound; contain immunomodulator, cyclosporin, and/or at least one cytokine or polyethylene glycol-cytokines |
| 01/27/2005 | US20050019367 Continuous release of luteinizing hormone releasing hormone (lh-rh) analogue of leuprorelin, buserelin, triptorelin, and/or goserelin |
| 01/27/2005 | US20050019347 Dna sequences and coding for hepatitis virus antigen |
| 01/27/2005 | US20050019341 Gene that codes tumor antigen is detected by cytotoxic lymphocyte; isolated from Dna libraries |
| 01/27/2005 | US20050019340 Oil in water emulsion; immunology response; using cancer antigen |
| 01/27/2005 | US20050019336 Human prostate cell lines in cancer treatment |
| 01/27/2005 | US20050019324 Peptides and antibodies to muc 1 proteins |
| 01/27/2005 | US20050019313 Genetic engineering; supplying stem cells; genes code cytosine deaminase; central nervous system tumors |
| 01/27/2005 | US20050019308 Administering reovirus; lysis of cancer cells |
| 01/27/2005 | US20050019307 Therapy gene against mammary gland cancer; transcription control ; Dna |
| 01/27/2005 | US20050019304 Novel human mage-like protein |
| 01/27/2005 | US20050019271 Glycopyrrolate in sustained releae form; antimuscarinic agents |
| 01/27/2005 | US20050019264 Imaging tissue with contrast agent such as Rose Bengal; medical diagnosis |
| 01/27/2005 | DE10330712A1 Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten Pharmarzeutischer agent against colon cancer and other tumor types |
| 01/27/2005 | CA2805464A1 Human antibody molecules for il-13 |
| 01/27/2005 | CA2804901A1 Human antibody molecules for il-13 |
| 01/27/2005 | CA2800212A1 Histone deacetylase inhibitors and methods of use thereof |
| 01/27/2005 | CA2539190A1 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 01/27/2005 | CA2532595A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 01/27/2005 | CA2532313A1 Medicament for treatment of dermal pigmentation |
| 01/27/2005 | CA2532122A1 Substituted tetrahydro-1h-pyrazolo[3,4-c]pyridines, compositions containing same and use |
| 01/27/2005 | CA2532078A1 Naphthylene derivatives as cytochrome p450 inhibitors |
| 01/27/2005 | CA2531596A1 Fluorocombretastatin and derivatives thereof |
| 01/27/2005 | CA2528383A1 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth |
| 01/27/2005 | CA2516652A1 System for external control of oncolytic virus replication |
| 01/26/2005 | EP1500702A1 APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy |
| 01/26/2005 | EP1500698A1 Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| 01/26/2005 | EP1500658A1 Novel thiol derivative, process for producing the same and use thereof |
| 01/26/2005 | EP1500655A1 New methionine aminopeptidase inhibitor |
| 01/26/2005 | EP1500643A1 Benzamide derivatives |
| 01/26/2005 | EP1500402A1 Cell death inhibitor |
| 01/26/2005 | EP1500400A1 Drug containing antibody composition |
| 01/26/2005 | EP1500398A1 Herbo-mineral formulation for refractory leukemias and lymphomas |
| 01/26/2005 | EP1499886A1 Methods and compositions for inducing an immune response |
| 01/26/2005 | EP1499746A1 Method to inhibit cell growth using oligonucleotides |
| 01/26/2005 | EP1499736A1 Improved chimeric glycoproteins and pseudotyped lentiviral vectors |
| 01/26/2005 | EP1499730A1 Immunoconjugates for the treatment of tumours |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499714A2 Regulation of human histone acetyltransferase |
| 01/26/2005 | EP1499631A2 Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina) |
| 01/26/2005 | EP1499619A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof |
| 01/26/2005 | EP1499617A1 Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
| 01/26/2005 | EP1499614A1 Adenosine a3 receptor modulators |
| 01/26/2005 | EP1499613A1 Thioxanthine derivatives as myeloperoxidase inhibitors |
| 01/26/2005 | EP1499610A2 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them |
| 01/26/2005 | EP1499606A1 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists |
| 01/26/2005 | EP1499605A2 NF-KappaB INHIBITORS |
| 01/26/2005 | EP1499600A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 01/26/2005 | EP1499599A1 Substituted pyrazine derivatives |
| 01/26/2005 | EP1499597A2 Compounds and methods for inducing apoptosis in proliferating cells |
| 01/26/2005 | EP1499595A1 Amonafide salts |
| 01/26/2005 | EP1499594A1 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles |
| 01/26/2005 | EP1499591A1 Carboxylic acid amides |
| 01/26/2005 | EP1499588A1 Melanocortin receptor ligands |
| 01/26/2005 | EP1499577A1 2-(2,6-dichlorophenyl)-diarylimidazoles |
| 01/26/2005 | EP1499392A1 Method and agents for the prevention, inhibition, and therapy of cancers |
| 01/26/2005 | EP1499362A1 Fusions of cytokines and tumor targeting proteins |
| 01/26/2005 | EP1499358A1 Ph-sensitive polymer |
| 01/26/2005 | EP1499353A2 Antibodies that specifically bind to tl5 |
| 01/26/2005 | EP1499352A1 Recombinant anti-interleukin-9 antibodies |
| 01/26/2005 | EP1499350A2 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 01/26/2005 | EP1499347A2 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 01/26/2005 | EP1499345A2 Protein a compositions and methods of use |
| 01/26/2005 | EP1499343A1 A method of modulating cellular activity |
| 01/26/2005 | EP1499338A1 7-hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof |
| 01/26/2005 | EP1499336A2 Protease inhibitors |
| 01/26/2005 | EP1499322A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy |
| 01/26/2005 | EP1499320A1 Novel compounds |
| 01/26/2005 | EP1499315A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia |
| 01/26/2005 | EP1499314A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders |
| 01/26/2005 | EP1499311A1 Substituted benzazoles and use thereof as raf kinase inhibitors |
| 01/26/2005 | EP1499308A2 Tri-substituted heteroaryls and methods of making and using the same |
| 01/26/2005 | EP1499307A1 Low-pressure mercury vapor discharge lamp |
| 01/26/2005 | EP1499299A2 Microparticle pharmaceutical compositions for intratumoral delivery |
| 01/26/2005 | EP1499187A2 Immunostimulatory g,u-containing oligoribonucleotides |
| 01/26/2005 | EP1441704B1 Orodispersible tablet having high homogeneity and the preparation method thereof |
| 01/26/2005 | EP1406610B1 Use of substituted gamma-lactone compounds as medicaments |